First-line liposomal irinotecan+5 fluorouracil/leucovorin plus oxaliplatin in patients with pancreatic ductal adenocarcinoma: Long-term follow-up results from a phase 1/2 study

被引：2
|
作者：
Wainberg, Z. [1 ]
Bekaii-Saab, T. [2 ]
Boland, P. [3 ]
Dayyani, F. [4 ]
Macarulla, T. [5 ,6 ]
Mody, K. [5 ,6 ,7 ]
Belanger, B. [8 ]
Maxwell, F. [9 ]
Moore, Y. [8 ]
Thiagalingam, A. [8 ]
Wang, T. [8 ]
Zhang, B. [8 ]
Dean, A. [10 ]
机构：
[1] Univ Calif Los Angeles, Los Angeles, CA USA
[2] Mayo Clin Phoenix, Phoenix, AZ USA
[3] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA
[4] Univ Calif Irvine, Med Ctr, Orange, CA 92668 USA
[5] Vall dHebron Univ Hosp, Barcelona, Spain
[6] Vall dHebron Inst Oncol, Barcelona, Spain
[7] Mayo Clin, Jacksonville, FL 32224 USA
[8] Ipsen, Cambridge, MA USA
[9] Ipsen, Abingdon, Oxon, England
[10] St John God Subiaco Hosp, Dept Oncol, Subiaco, WA, Australia
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.04.076
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA-1
引用
收藏
页码：S241 / S241
页数：1
相关论文
共 50 条
  • [21] Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study
    Lee, Jeeyun
    Jung, Kyung Hae
    Park, Young Suk
    Ahn, Joong Bae
    Shin, Sang Jun
    Im, Seock-Ah
    Oh, Do Youn
    Shin, Dong Bok
    Kim, Tae Won
    Lee, Namsu
    Byun, Jae Ho
    Hong, Yong Sang
    Park, Joon Oh
    Park, Se Hoon
    Lim, Ho Yeong
    Kang, Won Ki
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (04) : 657 - 663
  • [22] Liposomal irinotecan, oxaliplatin, and S-1 as first-line therapy for patients with locally advanced or metastatic pancreatic adenocarcinoma (NASOX): A multicenter phase I/IIa study
    Jeong, Hyehyun
    Kim, Bum Jun
    Lee, Choong-kun
    Park, Inkeun
    Zang, Dae Young
    Choi, Hye Jin
    Lee, Sang Soo
    Park, Do Hyun
    Song, Tae Jun
    Oh, Dongwook
    Moon, Sung-Hoon
    Kim, Kyu-pyo
    Wainberg, Zev
    Ryoo, Baek-Yeol
    Yoo, Changhoon
    EUROPEAN JOURNAL OF CANCER, 2024, 208
  • [23] Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study
    Kalofonos, HP
    Aravantinos, G
    Kosmidis, P
    Papakostas, P
    Economopoulos, T
    Dimopoulos, M
    Skarlos, D
    Bamias, A
    Pectasides, D
    Chalkidou, S
    Karina, M
    Koutras, A
    Samantas, E
    Bacoyiannis, C
    Samelis, GF
    Basdanis, G
    Kalfarentzos, F
    Fountzilas, G
    ANNALS OF ONCOLOGY, 2005, 16 (06) : 869 - 877
  • [24] A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy
    Sun Jin Sym
    Junshik Hong
    Jinny Park
    Eun Kyung Cho
    Jae Hoon Lee
    Yeon Ho Park
    Woon Ki Lee
    Min Chung
    Hyung-Sik Kim
    Se Hoon Park
    Dong Bok Shin
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 481 - 488
  • [25] A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy
    Sym, Sun Jin
    Hong, Junshik
    Park, Jinny
    Cho, Eun Kyung
    Lee, Jae Hoon
    Park, Yeon Ho
    Lee, Woon Ki
    Chung, Min
    Kim, Hyung-Sik
    Park, Se Hoon
    Shin, Dong Bok
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (02) : 481 - 488
  • [26] Liposomal irinotecan+5-fluorouracil/leucovorin plus oxaliplatin (NALIRIFOX) versus nab-paclitaxel plus gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma: Sensitivity analysis of survival from the NAPOLI 3 trial
    Wainberg, Z.
    Melisi, D.
    Macarulla, T.
    Cid, R. Pazo
    Chandana, S.
    de la Fouchardiere, C.
    Dean, A.
    Kiss, I.
    Lee, W.
    Goetze, T.
    Van Cutsem, E.
    Paulson, S.
    Bekaii-Saab, T.
    Pant, S.
    Hubner, R.
    Xiao, Z.
    Chen, H.
    Benzaghou, F.
    O'Reilly, E.
    ANNALS OF ONCOLOGY, 2023, 34 : S180 - S180
  • [27] Docetaxel, Oxaliplatin, and 5-Fluorouracil (DOF) in Metastatic and Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma: A Phase II Study with Long-Term Follow-Up
    Rosenberg, Ari Joseph
    Rademaker, Alfred
    Hochster, Howard S.
    Ryan, Theresa
    Hensing, Thomas
    Shankaran, Veena
    Baddi, Lisa
    Mahalingam, Devalingam
    Mulcahy, Mary F.
    Benson, Al B., III
    ONCOLOGIST, 2019, 24 (08): : 1039 - +
  • [28] Phase II study of infusional 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer: Final results
    Kopetz, S.
    Glover, K.
    Eng, C.
    Wolff, R.
    Chang, D.
    Adinin, R.
    Morris, J.
    Abbruzzese, S.
    Hoff, P.
    ANNALS OF ONCOLOGY, 2007, 18 : VII80 - VII80
  • [29] Final results of a randomized phase III trial in patients with advanced adenocarcinoma of the stomach receiving first-line chemotherapy with fluorouracil, leucovorin and oxaliplatin (FLO) versus fluorouracil, leucovorin and cisplatin (FLIP)
    Al-Batran, S. E.
    Hartmann, J. T.
    Probst, S.
    Hofheinz, R.
    Stoehlmacher, J.
    Pauligk, C.
    Hollerbach, S.
    Schuch, G.
    Homann, N.
    Jaeger, E.
    EJC SUPPLEMENTS, 2007, 5 (04): : 259 - 260
  • [30] PHASE II STUDY OF OXALIPLATIN COMBINED WITH LEUCOVORIN AND 5-FLUOROURACIL AS FIRST-LINE CHEMOTHERAPY IN PATIENTS WITH ADVANCED GASTRIC CANCER
    Lim, J. Y.
    Cho, J. Y.
    Jeung, H.
    Kim, S. H.
    Lee, J.
    ANNALS OF ONCOLOGY, 2008, 19 : 183 - 184
12345